Cannabis cigarettes vs placebo
The review found no eligible studies for this question.
- no estimate extractedStudies not reportedNo studies found
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Cannabidiol showed no clear difference in clinical response at 10 weeks compared with placebo (low certainty).
Cannabidiol probably leads to higher adverse events compared with placebo (moderate certainty).
Cannabidiol showed no clear difference in serious adverse events compared with placebo (low certainty).
Cannabidiol showed no clear difference in withdrawal due to adverse event compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Azathioprine may leads to lower failure to maintain remission compared with placebo (low certainty).
It is very uncertain whether the intervention changes acute pancreatitis (very low certainty).
It is very uncertain whether the intervention changes bone marrow suppression (very low certainty).
It is very uncertain whether azathioprine changes any adverse events compared with placebo (very low certainty).
It is very uncertain whether azathioprine changes withdrawal due to adverse event compared with placebo (very low certainty).
It is very uncertain whether azathioprine changes failure to maintain remission compared with sulfasalazine (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes failure to maintain remission compared with 5‐ASA (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes failure to maintain remission compared with methotrexate (very low certainty).
It is very uncertain whether azathioprine (AZA) changes failure to maintain remission compared with cyclosporin of remission (very low certainty).
It is very uncertain whether the intervention changes any adverse event (very low certainty).